Skip to main content
SpringerLink
Log in

Head and Neck Quality Assurance 2014

  • Chapter
  • First Online:
Head and Neck Cancer

  • 2388 Accesses

Abstract

Quality assurance (QA) in complex head and neck cancer trials is essential. The need for QA is made more relevant with trials comprised of multiple end points, worldwide participation, and increasing use of adaptive strategies/advanced technology to validate/verify outcome analyses. Integration is necessary for tissue analysis, biomarker assessment, imaging, radiation therapy, chemotherapy, and/or targeted therapy for patients with new diagnosis, relapse, and second head and neck malignancies.

Credentialing, data acquisition, management, review, and archive processes must be flexible and consistent for real-time review and validated results. Central to these comprehensive processes is a robust informatics platform for daily operation, data integrity, and communication. The ability to query well-constructed data repositories of clinical information, radiation and medical oncology, tissue, biomarker, and imaging objects is important to answer current and future questions. These libraries are extraordinary teaching resources.

Imaging, tissue, and biomarker analyses are key components of head and neck trials. Radiation therapy is a core treatment strategy, and trials will continue to study acute/late effects, tumor control, radiation dose-volume constraints, target definition, recurrence, and second malignancies.

QA remains the most invaluable construct to trial management. Protocol-compliant management provides consistent care through which new paradigms of care can be established and validated.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. FitzGerald TJ, Bishop-Jodoin M, Bosch WR, Curran WJ, Followill DS, Galvin JM, Hanusik R, King SR, Knopp MV, Laurie F, O’Meara E, Michalski JM, Saltz JH, Schnall MD, Schwartz L, Ulin K, Xiao Y, Urie M. Future vision for the quality assurance of oncology clinical trials. Front Oncol. 2013;3:31. doi:10.3389/fonc.2013.00031.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Tebbi CK, Mendenhall NP, London WB, et al. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2012;59(7):1259–65.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Tebbi CK, Mendenhall N, London WB, et al. Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study. Pediatr Blood Cancer. 2006;46(2):198–202.

    Article  CAS  PubMed  Google Scholar 

  4. Mendenhall NP, Meyer J, Williams J, et al. The impact of central quality assurance review prior to radiation therapy on protocol compliance: POG 9426, a trial in pediatric Hodgkin’s disease. Blood. 2005;106(11):753.

    Google Scholar 

  5. Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the Children’s Oncology Group study AHOD0031. J Clin Oncol. 2014;32(32):3651–8.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Dharmarajan KV, Friedman DL, Schwartz CL, et al. Patterns of relapse from a phase III study of response-based therapy for intermediate-risk Hodgkin Lymphoma (AHOD0031): a report from the Children’s Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92(1):60–6. pii: S0360-3016(14)04313-2.

    Article  PubMed  Google Scholar 

  7. Rischin D, Peters LJ, O’Sullivan B, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010;28(18):2989–95. Erratum in: J Clin Oncol. 2014;32(13):1386.

    Article  CAS  PubMed  Google Scholar 

  8. Peters LJ, O’Sullivan B, Giralt J, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol. 2010;28(18):2996–3001.

    Article  PubMed  Google Scholar 

  9. Ragaz J, Jackson S, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337(14):956–62.

    Article  CAS  PubMed  Google Scholar 

  10. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21(6):976–83.

    Article  CAS  PubMed  Google Scholar 

  11. Sartor CI, Peterson BL, Woolf S, et al. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344. J Clin Oncol. 2005;23(1):30–40.

    Article  CAS  PubMed  Google Scholar 

  12. Jagsi R, Chadha M, Moni J, et al. Radiation field design in the ACOSOG Z0011 (Alliance) trial. J Clin Oncol. 2014;32(32):3600–6.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Fairchild A, Straube W, Laurie F, et al. Does quality of radiation therapy predict outcomes of multicenter cooperative group trials? A literature review. Int J Radiat Oncol Biol Phys. 2013;87(2):246–60.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Tsien CI, Nyati MK, Ahsan A, et al. Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma. Head Neck. 2013;35(9):1323–30.

    Article  PubMed  Google Scholar 

  15. Vermorken JB, Psyrri A, Mesía R, et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol. 2014;25(4):801–7.

    Article  CAS  PubMed Central  Google Scholar 

  16. Vainshtein JM, Spector ME, McHugh JB, et al. Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer. Oral Oncol. 2014;50(5):513–9.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.

    Article  CAS  PubMed  Google Scholar 

  18. Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014;32(27):2940–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Boeckx C, Op de Beeck K, Wouters A, et al. Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins. Cancer Lett. 2014;354(2):365–77.

    Article  CAS  PubMed  Google Scholar 

  20. Wang Z, Martin D, Molinolo AA, et al. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst. 2014;106(9). doi:10.1093/jnci/dju215. pii: dju215.

  21. Vermorken JB, Mesia R, Rivera F, et al. Platinum based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.

    Article  CAS  PubMed  Google Scholar 

  22. Fan Z, Baselga J, Masui H, et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993;53(19):4637–42.

    CAS  PubMed  Google Scholar 

  23. Huang SM, Bock JM, Harari PM, et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinoma of the head and neck. Cancer Res. 1999;59(8):1935–40.

    CAS  PubMed  Google Scholar 

  24. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(24):5568–77.

    Article  CAS  PubMed  Google Scholar 

  25. Harari PM, Harris J, Kies MS, et al. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol. 2014;32(23):2486–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013;14(8):697–710.

    Article  CAS  PubMed  Google Scholar 

  27. Pajares B, Trigo JM, Toledo MD, et al. Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. BMC Cancer. 2013;13:26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Platzek I, Beuthien-Baumann B, Schneider M, et al. PET/MRI in head and neck cancer: initial experience. Eur J Nucl Med Mol Imaging. 2013;40(1):6–11.

    Article  PubMed  Google Scholar 

  29. Molineu A, Followill DS, Balter PA, et al. Design and implementation of an anthropomorphic quality assurance phantom for intensity-modulated radiation therapy for the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2005;63(2):577–83.

    Article  PubMed  Google Scholar 

  30. Molineu A, Hernandez N, Nguyen T, et al. Credentialing results from IMRT irradiations of an anthropomorphic head and neck phantom. Med Phys. 2013;40(2):022101.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Cadman P, Bassalow R, Sidhu NP, et al. Dosimetric considerations for validation of a sequential IMRT process with a commercial treatment planning system. Phys Med Biol. 2002;47(16):3001–10.

    Article  CAS  PubMed  Google Scholar 

  32. Feng M, Demiroz C, Vineberg KA, et al. Normal tissue anatomy for oropharyngeal cancer: contouring variability and its impact on optimization. Int J Radiat Oncol Biol Phys. 2012;84(2):e245–9.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Han C, Chen YJ, Liu A, et al. Actual dose variation of parotid glands and spinal cord for nasopharyngeal cancer patients during radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70(4):1256–62.

    Article  PubMed  Google Scholar 

  34. Leemans CR, Tijink BM, Langendijk JA, et al. Subcommittee of Surgery of the EORTC Head and Neck Cooperative Group. Quality assurance in head and neck surgical oncology: EORTC 24954 trial on larynx preservation. Eur J Surg Oncol. 2013;39(9):1013–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of Massachusetts Medical School/University of Mass Memorial Health Care, 55 N Lake Avenue, Worcester, MA, USA

    Thomas J. FitzGerald MD

  2. Department of Radiation Oncology, Marlborough Hospital, UMass Memorial Medical Center, Marlborough, MA, USA

    Thomas J. FitzGerald MD & Allison Sacher MD

  3. Department of Radiation Oncology, University of Massachusetts Medical School and the University of Massachusetts Memorial Health Care System, Worcester, MA, USA

    Thomas J. FitzGerald MD & David J. Goff MD

  4. Department of Radiation Oncology, University of Massachusetts Medical School, Lincoln, RI, USA

    Maryann Bishop-Jodoin MEd

  5. Section of Outreach Physics, Department of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    David S. Followill PhD

  6. Imaging and Radiation Oncology Core (IROC) for Clinical Trial QA, American College of Radiology, Philadelphia, PA, USA

    James M. Galvin DSc

  7. Department of Radiology, Wexner Medical Center, Ohio State University, Columbus, OH, USA

    Michael V. Knopp MD, PhD

  8. Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA

    Jeff M. Michalski MD, MBA

  9. Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA

    Mark Rosen MD, PhD

  10. Department of Radiation Oncology, UMass Memorial Medical Center, Worcester, MA, USA

    Jonathan M. Glanzman MD & Kenneth Ulin PhD

  11. Department of Radiation Oncology, University of Massachusetts, Worcester, Worcester, MA, USA

    Paul Rava MD, PhD

  12. Department of Otolaryngology, and Head and Neck Surgery, University of Massachusetts School of Medicine, Worcester, MA, USA

    Thomas J. FitzGerald MD & Alec Vaezi MD, PhD

Authors
  1. Thomas J. FitzGerald MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maryann Bishop-Jodoin MEd
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David S. Followill PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James M. Galvin DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael V. Knopp MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jeff M. Michalski MD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mark Rosen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jonathan M. Glanzman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Paul Rava MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Allison Sacher MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. David J. Goff MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Alec Vaezi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Kenneth Ulin PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas J. FitzGerald MD .

Editor information

Editors and Affiliations

  1. Department of Radio-Oncology, Genolier Swiss Medical Network, Genolier, Switzerland

    Jacques Bernier

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

FitzGerald, T.J. et al. (2016). Head and Neck Quality Assurance 2014. In: Bernier, J. (eds) Head and Neck Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-27601-4_52

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-27601-4_52

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-27599-4

  • Online ISBN: 978-3-319-27601-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation